分泌磷蛋白1(SPP1),也被称为骨桥蛋白,是磷酸化的蛋白质。已经在多种癌症中检测到高SPP1表达水平,并且与不良预后和降低的存活率相关。然而,只有少数泛癌症分析靶向SPP1。我们使用多个公共数据库进行了全面分析,包括TIMER和TCGA,探讨SPP1在33种不同类型肿瘤中的表达水平。此外,我们验证了SPP1对骨肉瘤的作用。为了评估SPP1对患者预后的影响,我们采用单变量Cox回归和Kaplan-Meier生存分析来分析总生存(OS),疾病特异性生存率(DSS),这些肿瘤患者的无进展间隔(PFI)。我们还使用cBioPortal探索了各种肿瘤组织中的SPP1基因改变。然后我们检查了SPP1和临床特征之间的关系,TME,免疫调节基因,免疫检查点,TMB,和MSI使用R语言。此外,我们使用GSEA研究了SPP1作用的分子机制。生物信息学分析表明SPP1在17例肿瘤中表达上调。SPP1的过表达导致操作系统差,DSS,和PFI在CESC,ESCA,GBM,LGG,LIHC,PAAD,PRAD,和皮肤皮肤黑色素瘤.SPP1表达与免疫细胞浸润呈正相关,免疫调节基因,免疫检查点,TMB,MSI,和某些癌症的药物敏感性。我们发现SPP1在骨肉瘤中的高表达与耐药和转移有关,并进一步证明SPP1可以通过激活PI3K/Akt通路通过CCND1刺激骨肉瘤细胞增殖。这些发现强烈表明SPP1是癌症免疫治疗的潜在预后标志物和新靶标。
Secreted phosphoprotein 1 (
SPP1), also known as osteopontin, is a phosphorylated protein. High SPP1 expression levels have been detected in multiple cancers and are associated with poor prognosis and reduced survival rates. However, only a few pan-cancer analyses have targeted
SPP1. We conducted a comprehensive analysis using multiple public databases, including TIMER and TCGA, to investigate the expression levels of SPP1 in 33 different tumor types. In addition, we verified the effect of
SPP1 on osteosarcoma. To assess the impact of SPP1 on patient outcomes, we employed univariate Cox regression and Kaplan-Meier survival analyses to analyze overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI) in these tumor patients. We also explored
SPP1 gene alterations in various tumor tissues using cBioPortal. We then examined the relationship between SPP1 and clinical characteristics, TME, immune regulatory genes, immune checkpoints, TMB, and MSI using R language. In addition, we used GSEA to investigate the molecular mechanisms underlying the role of SPP1. Bioinformatics analysis indicated that
SPP1 was upregulated in 17 tumors. Overexpression of SPP1 results in poor OS, DSS, and PFI in CESC, ESCA, GBM, LGG, LIHC, PAAD, PRAD, and skin cutaneous melanoma. SPP1 expression was positively associated with immunocyte infiltration, immune regulatory genes, immune checkpoints, TMB, MSI, and drug sensitivity in certain cancers. We found that high expression of SPP1 in osteosarcoma was related to drug resistance and metastasis and further demonstrated that SPP1 can stimulate osteosarcoma cell proliferation via CCND1 by activating the PI3K/Akt pathway. These findings strongly suggest that SPP1 is a potential prognostic marker and novel target for cancer immunotherapy.